Abstract Background and Objectives Cerebellar ataxia can be induced by a large number of
drugs. We here conducted a systemic review of the drugs that can lead to cerebellar ataxia …

Hyperammonemia (HA) commonly occurs with the use of valproic acid (VPA); while it has no
clinical significance in most cases, the Physician Desk Reference recommends its …

Objectives: Safety monitoring is an important aspect of bipolar disorder treatment, as mood‐
stabilising medications have potentially serious side effects, some of which may also …

INTRODUCTION: Valproate (VPA)-induced hyperammonemic encephalopathy (VHE) is a
serious drug-related adverse effect characterized by lethargy, vomiting, cognitive slowing …

The therapeutic efficacy of histone deacetylase inhibitors (HDACI) is generally attributed to
their ability to alter gene expression secondary to their effects on the acetylation status of …

Background Hyperammonemia is an adverse effect that poses clinical uncertainty around
valproic acid (VPA) use. The prevalence of symptomatic and asymptomatic …

Objective: The aim of this study was to investigate the effect of levocarnitine (active isoform
of carnitine, L-Carnitine) supplementation on serum ammonia and carnitine levels …

Purpose: Parents frequently report increased sleep duration in their children during
treatment with valproic acid (VPA). We assessed sleep duration and sleep behavior before …

Objective Sodium valproate (VPA) is a commonly prescribed antiepileptic drug (AED) in
daily neurosurgical practice. However, the incidence of VPA-associated hyperammonemia …

Metabolic encephalopathy is a rare but serious complication of valproic acid (VPA) therapy
that usually presents with impaired consciousness or increased seizure frequency. Although …